Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Andrew DeRyke

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Open Forum Infectious Diseases|July 26, 2021
Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of <i>Pseudomonas aeruginosa</i> From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards-SMART United States 2017-2019Sibylle H Lob, Daryl D DePestel, C Andrew DeRyke, et al.
Scandinavian Journal of Infectious Diseases|December 28, 2011
Over-treatment of carbapenemase-producing EnterobacteriaceaeDeba S Rihani, Mark R Wallace, Barry E Sieger, et al.
International Journal of Antimicrobial Agents|January 29, 2022
Prevalence of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates collected by the SMART global surveillance programme from 2015 to 2019James A Karlowsky, Sibylle H Lob, C Andrew DeRyke, et al.
Journal of the Pediatric Infectious Diseases Society|January 9, 2025
Antimicrobial Activity of Imipenem/Relebactam and Comparator Agents Against Gram-Negative Isolates Collected From Pediatric Patients: SMART 2018-2022 Global SurveillanceC Andrew DeRyke, Mark G Wise, Karri A Bauer, et al.
Antimicrobial Agents and Chemotherapy|January 26, 2026
Imipenem/cilastatin/relebactam dosing regimen justification using exposure-efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 studyMunjal Patel, Garrett Nieddu, C Andrew DeRyke, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 16, 2022
Activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa from patients in the Middle East and Africa - Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017-2020Sibylle H Lob, Mark A Estabrook, C Andrew DeRyke, et al.
Antibiotics (Basel, Switzerland)|May 28, 2022
Use of Novel Antibiograms to Determine the Need for Earlier Susceptibility Testing and Administration for New β-Lactam/β-Lactamase Inhibitors in the United StatesKenneth P Klinker, Levita K Hidayat, Eric Wenzler, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 20, 2023
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland-SMART 2017-2020Sibylle H Lob, Stephen P Hawser, Fakhar Siddiqui, et al.
The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases|May 11, 2023
In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020James A Karlowsky, Sibylle H Lob, Fakhar Siddiqui, et al.
Journal of Global Antimicrobial Resistance|December 13, 2021
In vitro activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries-SMART 2017-2019Sibylle H Lob, Krystyna M Kazmierczak, Wei-Ting Chen, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Open Forum Infectious Diseases|July 26, 2021
Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of <i>Pseudomonas aeruginosa</i> From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards-SMART United States 2017-2019Sibylle H Lob, Daryl D DePestel, C Andrew DeRyke, et al.
Scandinavian Journal of Infectious Diseases|December 28, 2011
Over-treatment of carbapenemase-producing EnterobacteriaceaeDeba S Rihani, Mark R Wallace, Barry E Sieger, et al.
International Journal of Antimicrobial Agents|January 29, 2022
Prevalence of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates collected by the SMART global surveillance programme from 2015 to 2019James A Karlowsky, Sibylle H Lob, C Andrew DeRyke, et al.
Journal of the Pediatric Infectious Diseases Society|January 9, 2025
Antimicrobial Activity of Imipenem/Relebactam and Comparator Agents Against Gram-Negative Isolates Collected From Pediatric Patients: SMART 2018-2022 Global SurveillanceC Andrew DeRyke, Mark G Wise, Karri A Bauer, et al.
Antimicrobial Agents and Chemotherapy|January 26, 2026
Imipenem/cilastatin/relebactam dosing regimen justification using exposure-efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 studyMunjal Patel, Garrett Nieddu, C Andrew DeRyke, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 16, 2022
Activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa from patients in the Middle East and Africa - Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017-2020Sibylle H Lob, Mark A Estabrook, C Andrew DeRyke, et al.
Antibiotics (Basel, Switzerland)|May 28, 2022
Use of Novel Antibiograms to Determine the Need for Earlier Susceptibility Testing and Administration for New β-Lactam/β-Lactamase Inhibitors in the United StatesKenneth P Klinker, Levita K Hidayat, Eric Wenzler, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 20, 2023
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland-SMART 2017-2020Sibylle H Lob, Stephen P Hawser, Fakhar Siddiqui, et al.
The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases|May 11, 2023
In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020James A Karlowsky, Sibylle H Lob, Fakhar Siddiqui, et al.
Journal of Global Antimicrobial Resistance|December 13, 2021
In vitro activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries-SMART 2017-2019Sibylle H Lob, Krystyna M Kazmierczak, Wei-Ting Chen, et al.
Pageof 5